B. Riley raised the firm's price target on ClearPoint Neuro to $20 from $18 and keeps a Buy rating on the shares. ClearPoint Neuro reported mixed Q4 results with strong 34% revenue growth but lowered 2026 guidance to reflect the removal of certain partner revenue and a reset of IRRAS's European distribution, while still expecting double-digit segment growth, the analyst tells investors in a research note. With roughly 13 partners now under FDA expedited review alongside potential FDA reversals and possible ex-U.S. approvals, the commercial gene therapy thesis appears increasingly de-risked with meaningful upside optionality, the firm says.
